Active Ingredient(s): Estradiol + Norethindrone Acetate + Relugolix
FDA Approved: * May 26, 2021
Category: Women's Health / Fertility

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Myfembree Overview

Relugolix/estradiol/norethisterone acetate (RGX/E2/NETA), sold under the brand name Myfembree, is a fixed-dose combination hormonal medication which is used for the treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.[1][2] It contains relugolix, an orally active gonadotropin-releasing hormone antagonist (GnRH antagonist), estradiol (E2), an estrogen, and norethisterone acetate (NETA), a progestin.[...

Read more Myfembree Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Myfembree Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Estradiol + Norethindrone Acetate + Relugolix
  • Tablet: 1mg + 0.5mg + 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (274 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 25 July 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA